Oct. 6, 2020, 3:44 p.m. EDT

BioMedNewsBreaks - Lineage Cell Therapeutics Inc. (US: LCTX) (tase:LCTX) Announces Broadening of Strategic Collaboration Regarding ESI Stem Cell Lines

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Lineage Cell Therapeutics Inc. (LCTX)
  • X
    AgeX Therapeutics Inc. (AGE)

or Cancel Already have a watchlist? Log In

/zigman2/quotes/207994235/composite LCTX -2.50%

Oct 06, 2020 (NetworkNewsWire via COMTEX) -- Lineage Cell Therapeutics /zigman2/quotes/207994235/composite LCTX -2.50% (tase:LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, together with its subsidiary ES Cell International Pte Ltd. ("ESI") and AgeX Therapeutics Inc. /zigman2/quotes/208090696/composite AGE -2.25% , a company focused on developing and commercializing innovative therapeutics for human aging, recently announced the broadening of their collaborative relationship regarding ESI stem cell lines. According to the update, ESI cell lines are current Good Manufacturing Practice ("cGMP")-compatible, registered with the National Institutes of Health ("NIH"), and widely studied as a potential source for the industrial-scale manufacture of any cell type in the human body. "Both Lineage and AgeX are pioneering important aspects of regenerative medicine. Working together, we have amended our agreement regarding ESI cell lines derived under cGMP to be optimal for the business needs of each company," Lineage's CEO Brian M. Culley said in the press release. "In particular, Lineage has acquired exclusivity for the use of ESI cell lines in spinal cord injury and certain oncology indications. On the other hand, AgeX has gained greater flexibility and independence to support its efforts toward licensing certain technologies and cell lines to third parties. With this step complete, we next intend to explore additional opportunities to collaborate with AgeX on promising tissue regenerating projects."

To view the full press release, visit: https://ibn.fm/9o6yw

About Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell-starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical programs are in markets with billion-dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen(R), a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer and in preclinical development for additional cancers and as a vaccine against infectious diseases, including SARS-CoV-2, the virus which causes COVID-19. For more information about the company, visit www.LineageCell.com .

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime . As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork .

COMTEX_372404174/2557/2020-10-06T15:44:02

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/207994235/composite
US : U.S.: NYSE American
$ 1.37
-0.03 -2.50%
Volume: 266,429
Nov. 30, 2020 12:08p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$209.99 million
Rev. per Employee
$26,873
loading...
/zigman2/quotes/207994235/composite
US : U.S.: NYSE American
$ 1.37
-0.03 -2.50%
Volume: 266,429
Nov. 30, 2020 12:08p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$209.99 million
Rev. per Employee
$26,873
loading...
/zigman2/quotes/208090696/composite
US : U.S.: NYSE American
$ 1.74
-0.04 -2.25%
Volume: 62,775
Nov. 30, 2020 12:03p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$67.09 million
Rev. per Employee
$101,647
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.